Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pre-Operative Bacterial Decolonization for Lower Extremity Wounds
NCT07142408Phase 3Recruiting
- Sponsor
- Cooper University Health Care
- Start
- Mar 2023
- Primary completion
- Oct 2030
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of chlorhexidine and mupirocin in surgical site infection (SSI) (2 arms), sponsored by Cooper University Health Care. Primary endpoint: Number of Participants with Surgical Site Wound Infection at 1 month. Started Mar 2023; status: recruiting.
02
Drugs
chlorhexidinemupirocin
03
Conditions
surgical site infection (SSI)
Beyond the preview
Go deeper on NCT07142408.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07142408.